apricus wealth LLC Sells 3,553 Shares of Pfizer Inc. $PFE

apricus wealth LLC cut its position in Pfizer Inc. (NYSE:PFE) by 3.2% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 107,238 shares of the biopharmaceutical company’s stock after selling 3,553 shares during the period. apricus wealth LLC’s holdings in Pfizer were worth $2,599,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. acquired a new stake in Pfizer in the 1st quarter worth about $27,000. North Capital Inc. bought a new position in shares of Pfizer during the first quarter worth approximately $28,000. Bayforest Capital Ltd acquired a new stake in shares of Pfizer in the first quarter valued at approximately $28,000. Harbor Asset Planning Inc. bought a new stake in shares of Pfizer in the second quarter valued at approximately $29,000. Finally, Horizon Financial Services LLC acquired a new stake in Pfizer during the first quarter worth approximately $35,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Bank of America boosted their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Finally, Morgan Stanley reduced their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $28.13.

Pfizer Trading Up 0.7%

Shares of Pfizer stock opened at $24.68 on Tuesday. The firm’s 50 day moving average is $24.89 and its 200 day moving average is $24.12. The firm has a market capitalization of $140.33 billion, a PE ratio of 13.13, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.22. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.